# Mineralocorticoid Receptor Antagonists in Type 2 Diabetes

> **NCT02809963** · PHASE4 · COMPLETED · sponsor: **Herlev Hospital** · enrollment: 140 (actual)

## Conditions studied

- Diabetes Type 2

## Interventions

- **DRUG:** Eplerenone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02809963
- **Lead sponsor:** Herlev Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2017-11
- **Final completion:** 2017-11
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2018-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02809963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02809963, "Mineralocorticoid Receptor Antagonists in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02809963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*